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Homozygous deletion frequency and expression levels of the CDKN2 gene
in human sarcomas - relationship to amplification and mRNA levels of
CDK4 and CCND1
GM Maelandsmo, J-M Berner, VA Florenes, A Forus, E Hovig, 0 Fodstad and 0 Myklebost
Department of Tumour Biology, The Norwegian Radium Hospital, 0310 Oslo, Norway.
Summary Homozygous deletions of the putative tumour-suppressor gene CDKN2, which encodes an
inhibitor of cdk4, have been detected in a high percentage of cancer cell lines of various histological types. In
the present study, 109 human sarcomas were examined for homozygous deletions and for mRNA expression
levels of the CDKN2 gene. Altogether, deletions were found in only eight (7%) of the cases, but, interestingly,
in two (of eight) malignant Schwannomas and in two (of five) rhabdomyosarcomas. In comparison, such
deletions were seen in only one (of 21) osteosarcomas and in none of 20 MFHs and 21 liposarcomas. Notably,
highly elevated CDKN2 mRNA levels were found in 33% of the sarcomas, whereas no detectable transcript
was present in 12 normal tissues. Amplifications of CDK4 and CCNDI (cyclin Dl) were observed in 11% and
4% of the sarcomas respectively, but never in tumours with CDKN2 deletions. The level of CDK4 mRNA
expression was increased in nine tumours in addition to the 12 samples with CDK4 amplification. Increased
levels of the cyclin Dl transcript was found in 37 cases, four with and 33 without amplification. The data
indicate that aberrations of these functionally related genes, or in regulation of the expression of the kinase,
the activator or the inhibitor, may participate in sarcoma development. Furthermore, the data suggest that
homozygous CDKN2 deletions may be of dissimilar significance in different sarcoma subtypes.
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Identification of various molecules involved in cell cycle
control has demonstrated a close association between regula-
tion of the cell cycle and neoplastic transformation. Thus,
derangements in the cell cycle machinery may play a critical
role in oncogenesis and contribute to uncontrolled cell
growth.
Recent results indicate that an inhibitor of the cell cycle,
the p16 protein, may be a new tumour suppressor. The gene
encoding p16, denoted either MTS1 (multiple tumour supp-
ressor 1) (Kamb et al., 1994), CDK41 (Nobori et al., 1994) or
CDKN2 (The HUGO Nomenclature Comittee designation),
is localised to human chromosome segment 9p21, a region
frequently found to contain cytogenetic abnormalities in
several types of cancer, including malignant melanomas,
gliomas, lung carcinomas and leukaemias (Kamb et al., 1994;
Nobori et al., 1994). Moreover, the gene has been found to
be homozygously deleted or mutated in a high percentage of
cell lines derived from tumours of various histological types
(Kamb et al., 1994). On this background CDKN2 has been
suggested to be involved in the formation of malignancies
originating from a wide range of tissues (Kamb et al., 1994).
p16 was originally identified when searching for proteins
able to associate with the cell cycle regulating enzyme cyclin-
dependent kinase 4 (cdk4) (Serrano et al., 1993). Cdk4 is,
when activated by cyclin Dl, able to phosphorylate the
retinoblastoma tumour-suppressor protein (pRb), resulting in
release of pRb-mediated GI arrest. Since p16 can bind to
cdk4 and thereby inhibit the catalytic activity of the cyclin
Dl-cdk4 complex, the protein seems to participate in a
regulatory pathway together with cdk4, cyclin Dl and pRb.
Alterations of cyclin Dl and cdk4 have also been suggested
to be involved in oncogenesis (Khatib et al., 1993; Motokura
and Arnold, 1993). Thus, translocations involving the ql3
segment of chromosome 11, harbouring the cyclin Dl gene
(CCNDI), have frequently been observed in parathyroid
adenomas and B-cell lymphomas (Motokura and Arnold,
1993). In addition, CCND1 has been found amplified and
overexpressed in breast (Lammie et al., 1991) and oeso-
phageal carcinomas (Jiang et al., 1992). Similarly, the
amplification and overexpression of CDK4, localised to
chromosome band 12q13, has been suggested to contribute to
deranged growth control in some sarcomas (Khatib et al.,
1993; Forus et al., 1995).
As most studies on CDKN2 so far have been performed on
cell lines, it is still unclear to what extent deletions and
mutations of this gene are a result of in vitro cell cultivation
or represent a critical step in cancer development.
Preliminary reports indicate that p16 aberrations are not as
frequent in biopsied tumour material as first anticipated
(Cairns et al., 1994; Spruck et al., 1994). In an attempt to
determine the possible involvement of CDKN2 in sarcoma
tumorigenesis, we screened a panel of 109 tumours for
homozygous deletions of CDKN2. In parallel, the
amplification frequency of the functionally related genes
CDK4 and CCND1 was studied. Furthermore, the mRNA
levels of the three genes were determined to examine to what
extent the DNA status of the tumours was reflected at the
transcriptional level, or if aberrant gene expression could be
observed in tumours without detectable deletions or
amplifications. It was also of interest to analyse whether a
consistent co-variation might exist between the mRNA levels
of the genes encoding the kinase (cdk4), the activator (cyclin
Dl) and the inhibitor (pl6).
Materials and methods
Specimens
Sarcoma tissue of different histological subtypes was
obtained from 77 patients and from 27 human tumour
xenografts in nude mice. In five cases, both patient and
xenograft material was available. In addition, five human
sarcoma cell lines and a panel of 12 normal tissue samples
representing mononucleated cells from peripheral blood,
kidney, colon, liver, salivary gland, brain, lung, placenta,
striated muscle, breast gland, ovary and skin were studied.
The different sarcoma subtypes were represented by two
chondrosarcomas, 21 osteosarcomas, two carcinosarcomas,
five fibrosarcomas, one haemangiopericytoma, 13 leiomyosar-
comas, 21 liposarcomas, 20 malignant fibrous histiocytomas
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(MFHs), eight malignant Schwannomas, five rhabdomyosar-
comas and 11 non-classified sarcomas. The last group
included one undifferentiated, one neuroectodermal and one
monocyte-like sarcoma. Immediately upon surgery, the
tumour tissue was frozen into liquid nitrogen and subse-
quently stored at - 135°C.
Southern blot analysis
Genomic DNA from sarcoma tissue was isolated by standard
methods (Maniatis et al., 1982). Aliquots (7fig) of DNA
were digested with HindIII, separated on 0.8% agarose gels
and transferred by alkaline blotting onto Hybond N+mem-
branes (Amersham, Amersham, UK), according to the
manufacturer's manual. After UV cross-linking for 5 min, the
blots were prehybridised for 2 h and subsequently hybridised
with DNA probes labelled with 32P by the random primer
technique (Feinberg and Vogelstein, 1983). The hybridisation
was carried out in 50% formamide, 6 x standard saline cit-
rate (20 x SSC = 3.0M sodium chloride, 0.3 M sodium cit-
rate), 0.5% sodium dodecyl sulphate (SDS), 1.5 x Denhardt's
(50 x Denhardt's = 1% Ficoll, 1% bovine serum albumin,
1% polyvinylpyrrolidone) and 100jig ml1 denatured salmon
sperm DNA at 42°C over night as described by Maniatis et
al. (1982). After hybridisation, the membranes were washed
for 20 min at 65°C subsequently in 2 x SSC/0.5% SDS,
1 x SSC/0.5% SDS and 0.5 x SSC/0.5% SDS. For multiple
hybridisations, the bound probe was removed by incubating
the filters for 15 min at room temperature in 100 mM sodium
hydroxide and 1 mM sodium EDTA.
Samples with a signal weaker than 25% when compared
with the signal from a reference lane were scored as having a
homozygous deletion of the corresponding gene. A signal at
least 3-fold more intense than signals from samples with a
normal copy number of the gene was scored as an
amplification. Densitometric analysis of the autoradiograms
was used to decide in cases that were not obvious. To adjust
for unequal amounts of loaded DNA, the blots were rehyb-
ridised to a control probe encoding apolipoprotein B, located
on chromosome 2.
Northern blot analysis
Total cellular RNA was prepared by the guanidinium thio-
cyanate-caesium chloride method described by Maniatis et
al. (1982). Samples of 5 tg of total RNA were separated by
1% agarose-formaldehyde gel electrophoresis and blotted
onto HybondN+membranes (Amersham, Amersham, UK)
according to the manufacturer's manual. After baking for 2 h
and subsequent ultraviolet cross-linking, the filters were hyb-
ridised with DNA probes labelled with 32P by the random
primer method (Feinberg and Vogelstein, 1983). The hyb-
ridisations were carried out in 0.5 M sodium phosphate (pH
7.2), 7% SDS and 1 mM sodium EDTA overnight at 65°C as
described by Church and Gilbert, (1984). The membranes
were subsequently washed three times for 15 min in 40mM
sodium phosphate (pH 7.2) and 1% SDS. For multiple hyb-
ridisations the bound probe was removed by incubating the
filters twice for 5 min in 0.1 x SSC and 0.1% SDS at
95-100°C.
To correct for uneven amount of RNA loaded in each
lane, the filters were rehybridised with a kinase-labelled
(Maniatis et al., 1982) oligonucleotide probe specific for
human 18S rRNA. The mRNA expression levels were
classified as follows: '-/+', undetectable/low expression;
'+ +' and '+ + +', high or very high expression.
Probes
The following probes were used: CCND1 cDNA kindly pro-
vided by Dr D Beach, Howard Hughes Medical Institute,
Cold Spring Harbor, NY, USA; and CDK4 cDNA by Dr P
Meltzer, National Institute of Health, Bethesda, MD, USA.
As probe for CDKN2 a 929 bp PCR product was used,
amplified from a plasmid encoding the CDKN2 cDNA (Dr D
Beach) with primers suggested by Kamb et al. (1994). The
APOB clone pB27, kindly provided by Dr J Breslow,
Rockefeller University, New York, NY, USA, and a human
specific oligonucletide probe complementary to nucleotides
287-305 of 18S rRNA were used as control probes for the
Southern and Northern blots respectively.
Results
Southern blot analysis
DNA from 109 human sarcomas of various histological sub-
types was analysed for homozygous deletions of the putative
tumour-suppressor gene CDKN2 and for amplification of
CDK4 and CCDN1 (Table I and Figure 1). Homozygous
deletion of CDKN2 was found in eight tumours (7%), includ-
ing two rhabdomyosarcomas, two malignant Schwannomas,
one chondrosarcoma, one leiomyosarcoma, one osteosar-
coma and one non-classified sarcoma. Six of these samples
were obtained directly from patients (6/77 = 8%), one speci-
men was a xenograft (1/27 = 4%) and one was a cultured cell
line (1/5 = 20%).
Amplification of CDK4 was observed in 12 cases, including
four lipo-, two osteo- and two fibrosarcomas and in one
haemangiopericytoma, malignant Schwannoma, rhabdomyo-
sarcoma and a non-classified sarcoma. CCND1 amplification
was found in only four cases: one osteosarcoma, one
haemangiopericytoma, one liposarcoma and one non-class-
ified sarcoma. Interestingly, none of the tumours with
CDKN2 deletions showed amplification of any of the two
other genes, whereas three of the four cases with amplified
CCND1 also had amplification of CDK4. When adding up
the alterations involving the CDKN2, CDK4 and CCND1
genes, the total number of aberrations in this pathway inc-
reases to 21 cases (Table I).
Northern blot analysis
To examine the association between DNA status and gene
expression at the mRNA level, total RNA was extracted
from 100 of the 109 tumours and from a panel of 12 different
normal tissue samples.
As expected, no CDKN2 mRNA was detected in tumours
with homozygous deletion of the gene, whereas these cases
expressed variable amounts of mRNA for both cdk4 and
cyclin Dl (Figure 2 and Table I). Interestingly, although
none of the 12 normal tissues examined expressed detectable
levels of the CDKN2 transcript, 33 of the sarcomas (33%)
showed high to very high mRNA levels ('+ +' or '+ + +'),
of which 18 were patient biopsies (14 primary tumours and
four metastatic lesions, i.e. 26% of the patient biopsies),
whereas 13 originated from xenografts (48% of the xenog-
rafts) and two were in vitro cell lines (50%) (Table II).
All 12 tumours with CDK4 amplification demonstrated a
high ('+ +' or '+ + +') transcript level, and 11 of these
tumours showed a concomitant high expression of one of the
two other genes (Figure 2 and Table I). Moreover, high
('+ +') CDK4 expression was found also in nine tumours
without amplification of the gene (Table II). Altogether,
elevated CDK4 transcript levels were present in biopsies from
11 patients (16%), in seven sarcoma xenografts (26%) and in
three in vitro cell lines (75%). The expression levels in normal
tissues varied. Thus, specimens obtained from kidney, lung,
ovary and breast gland showed a high ('+ +') expression,
whereas the other tissues demonstrated a low, but detectable
('+') CDK4 mRNA level.
Except for lung and skin, the mRNA level of CCND1 was
generally low in the normal tissues. In contrast, high expres-
sion levels were found in 37 sarcomas (37%), of which 24
were tumour biopsies (35% of the patient biopsies), 12
xenografts (44%) and one of four cultured cell lines (Table
II). Unlike the results of the other transcripts, the expression
patterns of CCND1 differed in the two main groups of
sarcomas. Thus, whereas 42% of the soft-tissue tumoursHomozygous deleion ofCDKN2 in sarcomas
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Table I Tumours with DNA' deletion or amplification affecting either of the CDKN2, CDK4 or
CCND1 genes. Relationship to the mRNA levelsb
Tumours' with
DNA aberrations
(total no. oftumours CDKN2 CDK4 CCNDI
ofeach subtype) DNA mRNA DNA mRNA DNA mRNA
Osteosarcoma (n = 21)
OS6x N +(+) A + + N (-)
OSllp D - N +++ N +
OSAcl N +++ A +++ A +++
Chondrosarcoma (n = 2)
CS2p D - N (+) N ++
Fibrosarcoma (n = 5)
FSlp N ++ A +++ N +
FS2p N (+) A ++ N ++
Haemangiopericytoma (n= 1)
HPlx N ++ A +++ A +++
Leiomyosarcoma (n = 13)
LMS8p D N (+) N + + +
Liposarcoma (n = 21)
LS2p N (+) N (+) A + + +
LSIlp N ++ A +++ N +++
LS21p N ++ A +++ N +
LS22p N (+) A + + N + +
LS28x N +++ A +++ N ++
Malignant Schwannoma (n = 8)
MS2x D - N + N + +
MS7p D - N ++ N +
MS8p N ++ A +++ N +
Rhabdomyosarcoma (n = 5)
RMS3p D - N + N -
RMS4cl D - N + + + N +
RMS13cl N +++ A +++ N ++
Non-classified sarcoma (n = 11)
NCS2x N +++ A +++ A +++
NCS7p D - N + N (+)
No. of tumours with
DNA alterations 8 12 4
aN, normal; D, deletion; A, amplification. bExpression levels as described in Materials and
methods. Ccl, cell line; p, patient biopsy; x, xenograft. Altogether 109 tumours.
expressed high levels of cyclin DI mRNA, only 22% of the
osteogenic sarcomas did so.
Relationship between the mRNA levels ofCDKN2, CDK4 and
CCNDI
Of the 33 tumours found to express high levels of mRNA
encoding the cdk4 inhibitor, 25 (76%) had low or undetec-
table level of the CCND1 transcript. Conversely, of the 37
tumours with high CCND1 expression, 29 (78%) did not
express detectable amounts of the inhibitor mRNA. Taken
together, these results suggest an inverse relationship between
the mRNA levels of the kinase inhibitor and the kinase
activator (two-sided Fischer exact test, P = 0.08).
In 10 of the 33 tumours the elevated inhibitor expression
was accompanied by a high level of CDK4 mRNA, including
nine cases with amplification of the kinase gene. Only five
tumours, all with amplification of CDK4, showed high ex-
pression of all three genes.
Discussion
The CDKN2 gene, encoding an inhibitor of cdk4 activity,
was recently reported to be homozygously deleted in a high
percentage of human cancer cell lines (Kamb et al., 1994;
Nobori et al., 1994). Based on these results it was suggested
that the inhibitor, p16, may be an important new tumour-
suppressor protein (Kamb et al., 1994). By binding to cdk4,
p16 inhibits the formation of the cyclin Dl-cdk4 complex,
which is known to phosphorylate and thereby inactivate the
retinoblastoma protein (Serrano et al., 1993). The loss ofp16
expression caused by gene deletion may result in increased
cdk4-induced phosphorylation of pRb, thus releasing the GI
cell cycle block.
To investigate whether CDKN2 aberations might be
involved in the tumorigenesis of human sarcoma, a panel of
more than 100 tumours of various histological subtypes was
analysed for homozygous deletions of the gene. It was found
that only eight of the sarcomas showed such deletions.
Notably, no deletion of CDKN2 was seen in any of the 21
liposarcomas and 20 MFHs studied, and in only one of 21
osteosarcomas. The low deletion frequency stands in contrast
to the 25-87% homozygous deletions found in various
human tumour cell lines, including 60% of the human
osteosarcoma cell lines studied (Kamb et al., 1994; Nobori et
al., 1994). Interestingly, however, we found that two ofeight
malignant Schwannomas and two of five rhabdomyosar-
comas had lost CDKN2, suggesting that homozygous dele-
tions of CDKN2 might be of different importance in the
development of various sarcoma subtypes. The overall low
incidence of deletions found here is in accordance with the
results of Spruck et al. (1994) and Cairns et al. (1994), who
observed homozygous deletions that included the CDKN2
gene only in about 10-20% ofbladder, brain, head and neck
and lung carcinomas. Conceivably, the high deletion fre-
quency observed in cell lines might be a result of in vitro cell
cultivation. Our data do not permit any conclusions on this,
but it was found that one of five sarcoma cell lines had lost
the CDKN2 gene, whereas only one of 27 (4%) sarcomasHomozygous deletion ofCDK&2 in sarcomas
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Figure 1 Representative Southern blot analysis demonstrating homozygous deletion of CDKN2 (a and b) and amplification of
CDK4 and CCNDI (a). The DNA (7 fig in each lane), digested with HindIII, was subsequently hybridised with probes encoding the
three different genes and, as a control, with an APOB probe. Samples with DNA aberrations, scored as described in Materials and
methods, are indicated by a D (deletion) or A (amplification) below the corresponding panel. For the MS8 tumour, two additional
bands emerged with the CCNDI cDNA probe owing to cross-hybridisation of cyclin D2 which is amplified in this tumour.
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Figure 2 Northern blot analysis demonstrating the mRNA levels
of CDKN2, CDK4 and CCNDI in the same sarcomas as listed in
Figure la and the OSA cell line. Five micrograms of total RNA
in each lane was subsequently hybridised with probes encoding
the three different genes, and as a control with an 18 S rRNA
oligonucleotide probe.
grown as xenografts in nude mice harboured such lesions.
When tumour material and xenografts established from the
same patient could be examined, identical results on CDKN2
aberrations were obtained, indicating that the process of
xenografting does not induce homozygous deletion of the
gene, in accordance with the results of Caldas et al. (1994).
The possibility exists that the somewhat contradicting
reports concerning the incidence of homozygous CDKN2
deletions might in part be related to methodological factors.
Despite careful dissection of the tumour tissue before freez-
ing, infiltration of normal cells in the tumour biopsy could
result in a low observed deletion frequency. However,
Southern blot analysis, as used here, should be less sensitive
to a moderate contribution from normal tissue than the PCR
analysis used by others (Cairns et al., 1994; Kamb et al.,
1994; Nobori et al., 1994; Spruck et al., 1994).
Furthermore, it should be noted that part of our sarcoma
material has previously been analysed for loss of
heterozygosity of the TP53 gene without any indications of
normal cell DNA affecting the results (Andreassen et al.,
1993). It cannot be excluded that the CDKN2 gene may be
inactivated by mechanisms other than loss of the entire gene,
including point mutations and small deletions, as have been
reported in cases of oesophageal (Mori et al., 1994), non-
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Table II Tumours with elevated mRNA expression
No. ofcases with high to very high mRNA levelsa
Source ofsample No. analysed CDKN2 CDK4 CCNDI
Tumour tissue 69 18 11 24
Xenografts 27 13 7 12
Cell lines 4 2 3 1
Total 100 33 (33%) 21 (21%) 37 (37%)
aScored as described in Materials and methods.
small-cell lung (Hayashi et al., 1994) and pancreatic car-
cinomas (Caldas et al., 1994). Thus, in order to reveal wheth-
er such abnormalities may be important in the tumorigenicity
of sarcomas, the tumours will be analysed for mutations in
exon 1 and 2.
The mechanism of action of the p16 inhibitor made it of
interest to examine the tumour panel for aberrations also in
the genes encoding cdk4 and cyclin Dl. CDK4 has previously
been found amplified in sarcoma cell lines (Khatib et al.,
1993) and tumour biopsies (Forus et al., 1995). Moreover,
deregulation of the CCND1 gene has been observed in
several cancer forms, caused either by tumour-specific gene
translocation (Motokura and Arnold, 1993) or by gene
amplification (Lammie et al., 1991). CDK4 is located in the
q13-14 region of human chromosome 12, and amplification
of genes in this chromosomal segment has frequently been
observed in human sarcomas (Forus et al., 1993; Demetrick
et al., 1994). In the present work, CDK4 amplification was
observed in 12 cases, and in three of these tumours CCND1
was also amplified. It might be speculated that there is a
synergistic growth advantage when both genes are amplified.
Amplification of CDK4 and/or of CCND1 found in the
tumour biopsies was never accompanied by CDKN2 deletion.
This is in accordance with the view that this growth-
regulating pathway can be deregulated either by a loss of the
inhibitor or by an increase in the amount of the rate-limiting
cyclin Dl/cdk4 complex. Most of our samples have been
examined for amplification also of the two other D-type
cyclins, cyclin D2 and cyclin D3, both able to form a com-
plex with cdk4 in a similar way as cyclin DI (Bates et al.,
1994). These genes were amplified in only one case each, both
concomitant with amplification of CDK4 but not of CCND1
(results not shown).
The mRNA levels of CDK4, CCND1 and CDKN2 were
examined in an attempt to detect possible consistent patterns
of co-variation between the three transcripts, and to relate
the results to the DNA status. Although caution must be
taken when drawing conclusions on the activity of their
associated gene products, it has been reported that the
amount of cyclin Dl-cdk4 complex varies in relation to the
CDK4 mRNA levels (Pines, 1993) and that synthesis of
cyclin Dl, a protein with short half-life, is necessary and rate
limiting for GI progression (Matsushime et al., 1991; Baldin
et al., 1993; Hunter and Pines, 1994). Taken together, this
indicates that the mRNA levels might be informative for the
protein activities.
Interestingly, and surprisingly for a cell cycle inhibitor,
33% of our tumours showed large amounts of CDKN2
mRNA compared with undetectable levels in all normal tis-
sue samples examined. Moreover, in 25 of the 33 cases, high
inhibitor mRNA expression was accompanied by absent or
only negligible levels of the CCND1 transcript. Conversely,
most of the sarcomas with high cyclin Dl expression (37%)
showed low expression of the inhibitor, suggesting an inverse
relationship between these two transcripts. The tumour-
promoting effects of p16, cdk4 or cyclin Dl aberrations are
mnct lit-plu AlIIA tn th,.ir ^Ivrvne thn, _crfle;
the retinoblastoma protein, and thus on entry into S-phase.
The cdk4 inhibitor is suggested to function as a negative
regulator of cdk4 once pRb has been inactivated by phos-
phorylation (Serano et al., 1993). In cells in which the pRb
tumour-suppressor protein is constitutively inactivated, p16
expression is hypothesised to be elevated with a subsequent
inhibition ofthe kinase (Serrano et al., 1993). Furthermore, it
has been shown that the CCND1 expression may be
positively regulated at the transcriptional level by active,
unphosphorylated pRb (Bates et al., 1994; Hunter and Pines,
1994; Muller et al., 1994). Therefore, it seems reasonable to
assume that cells with low expression of CCND1 and
elevated expression of CDKN2 may be pRb deficient, and
studies to examine this hypothesis have been initiated.
Only 4 of the 37 sarcomas with elevated CCND1 mRNA
levels had amplification of the gene. Similarly, in breast
carcinomas elevated levels of cyclin Dl mRNA and protein
have been found to occur without concomitant gene aberra-
tions, suggesting that other molecular mechanisms may
induce overexpression of the cyclin Dl gene (Buckley et al.,
1993; Bartkova et al., 1994). Elevated cyclin Dl expression
may overcome pRb-mediated growth inhibition, as has been
demonstrated in oesophageal (Jiang et al., 1993) and non-
small-cell lung carcinomas (Schauer et al., 1994). It has been
speculated whether other mechanisms than cyclin Dl-cdk4
mediated pRb phosphorylation may be involved, as no phos-
phorylated tumour-suppressor protein was detected when
cyclin Dl and pRb were cotransfected into SaOS-2 cells
(Hinds et al., 1992; Dowdy et al., 1993). Thus, it is possible
that such mechanisms might help explain the high fraction of
sarcomas expressing elevated levels of cyclin Dl mRNA.
In summary, although the overall frequency of homo-
zygous deletions of CDKN2 was found to be low in sar-
comas, the indication of a higher incidence of such deletions
among the malignant Schwannomas and rhabdomyosar-
comas suggests that inactivation of the gene may be of
particular significance in the development of these sarcoma
subtypes. The overexpression of CDKN2 observed in a con-
siderable fraction ofall the sarcomas studied might be related
to pRb deficiency or to mechanisms stabilising the mRNA.
Moreover, the high fraction of sarcomas with amplification
and/or increased mRNA levels of CDK4 and CCND1 further
supports the view that disturbance of this pathway may be of
importance in the tumorigenesis of sarcomas.
Abbreviations
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